HHS extends COVID-19 public health emergency for another 90 days GSK inks $1.9B Sierra takeover as $3M bet on Gilead castoff turns into blockbuster buyout J&J, 2-stepping through talc litigation, faces fresh claims it hid worker's asbestos exposure FDA approves Boston Scientific's 3D visualization software to program neurostim devices ProQR slashes 30% of workforce following phase 2/3 blunder AbbVie president Severino departs to help pilot Flagship Pioneering Mirvie mRNA study predicts premature births 2 months in advance J&J, Roche partner Halozyme buys Antares Pharma for $1B, beefing up drug delivery offerings Northwell Health-backed JV invests $100M in AI companies tackling health inequities Prevencio's AI blood test predicts cardiovascular risk one year out for people with diabetes: study Nationwide drug spending grew 7.7% in 2021, will increase another 4%-6% in 2022 Bristol Myers Squibb Foundation unites with Gilead to boost diversity among clinical trial investigators Featured Story | By Robert King HHS Secretary Xavier Becerra has extended the COVID-19 public health emergency for another 90 days, creating potentially the last extension. read more |
| |
|---|
|
|
| Full-time Consulting Careers IPM is an industry leader in Life Sciences consulting and has managed projects for more than 150 biotech, pharma, and medtech companies. Learn how you can lead a variety of impactful projects with us. Explore here! |
Top Stories By Nick Paul Taylor GlaxoSmithKline has struck a deal to buy Sierra Oncology for $1.9 billion for a near-approval cancer drug, completing a remarkable turnaround for the biotech and the Gilead castoff it bet its future on. read more By Fraiser Kansteiner U.S. bankruptcy judge Michael Kaplan this week denied J&J’s bid to block a lawsuit accusing the company of hiding evidence that its industrial talc operations exposed workers to asbestos, Bloomberg first reported. read more By Andrea Park The stateside approval comes nearly two and a half years after the Stimview XT software received CE mark clearance in Europe in late 2019. read more By Max Bayer Ophthalmology-focused ProQR is axing 30% of its workforce, including its chief scientific officer, and re-strategizing, more than two months after its most developed asset, sepofarsen, failed to improve vision in kids with congenital eye disease in a phase 2/3 trial. read more By Fraiser Kansteiner Life sciences investor Flagship Pioneering is breaking out the big guns. Days after enlisting execs from Ancestry.com and Novartis, the company has tapped one of its biggest CEO-partners since snagging former FDA commissioner Stephen Hahn, M.D., in June. read more By Andrea Park San Francisco-based startup Mirvie is attempting to open up an earlier diagnostic window in the second trimester, in hopes of expanding the treatment options for patients predicted to experience preterm birth. read more By Angus Liu Halozyme is best known for its under-the-skin drug delivery platform, with partnerships with the likes of Johnson & Johnson, GlaxoSmithKline and Roche. The company is now buying into the auto-injector realm and setting out to cultivate an internal commercial team. read more By Heather Landi NEW YORK, New York—Northwell Health's JV, called Ascertain, plans to use $100 million to launch multiple AI companies in 2022 to tackle health inequities, with an initial focus on maternal health and chronic disease detection, executives announced Tuesday. read more By Conor Hale By using AI to analyze dozens of proteins at once, Prevencio showed its blood test could be accurate in predicting whether a person with diabetes may have a heart attack or stroke within the coming year. read more By Dave Muoio Nonfederal hospitals saw an 8.4% increase in drug spending during 2021 while clinics shouldered a 7.7% gain, according to a recent report from the American Society of Health-System Pharmacists. read more By Max Bayer The Bristol Myers Squibb Foundation is expanding its two initiatives aimed at bolstering diversity among clinical trial investigators, adding Gilead as a sponsor. read more |
